TrialCell reports. Medicine2025

Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response.

Thierry Alcindor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.